----

----

| (Mark One) |
|------------|
| þ     |   | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

| o |   | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|--------|------------------------------------------------------------------------------------------|

|   | WaferGen Bio-systems, Inc.                             |   |
|--------|--------------------------------------------------------|--------|
|   | (Exact Name of Registrant as Specified in its Charter) |   |

|   | Nevada                                                         |   | 90-0416683                        |   |
|--------|----------------------------------------------------------------|--------|-----------------------------------|--------|
|   | (State or other jurisdiction of incorporation or organization) |   | (IRS Employer Identification No.) |   |

|   | 7400 Paseo Padre Parkway, Fremont, CA    |   | 94555      |   |
|--------|------------------------------------------|--------|------------|--------|
|   | (Address of principal executive offices) |   | (Zip Code) |   |

|   | (510) 651-4450                                           |   |
|--------|----------------------------------------------------------|--------|
|   | Registrant’s telephone number, including area code |   |

|   | Title of each class: None | Name of each exchange on which registered: None |   |
|--------|---------------------------|-------------------------------------------------|--------|

| Large accelerated filer  ̈                                                        | Accelerated filer  ̈         |
|--------------------------------------------------------------------------------------------|---------------------------------------|
| Non-accelerated filer  ̈  (Do not check if a smaller reporting company) | Smaller reporting company þ |

----

----

|          |                                                                                        | Page    |   |
|---------------|---------------------------------------------------------------------------------------------|---------|--------|
|          | FORWARD LOOKING STATEMENTS                                                                  | 1       |   |
|          | PART II                                                                                     |    |   |
| ITEM 7.       | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 2  |   |
| ITEM 8.       | Financial Statements and Supplementary Data                                                 | 11      |   |
| ITEM 9A(T).   | Controls and Procedures                                                                     | 44      |   |
|          |                                                                                        |    |   |
|          | PART IV                                                                                     |    |   |
| ITEM 15.      | Exhibits and Financial Statement Schedules                                                  | 46      |   |
|          |                                                                                        |    |   |
| SIGNATURES    |                                                                                        | 49      |   |
|          |                                                                                        |    |   |
| EXHIBIT INDEX | 50                                                                                          |    |

----

----

----

|                                           |   | Year Ended December 31, |
|------------------------------------------------|--------|----------------------------------------|
|                                           |   | 2009                                   |   |   | 2008 |
|                                           |   |                                   |   |   |   |
| Revenue                                        |   | $                                      | 379,373 |   |   | $ | 621,866 |   |
|                                           |   |                                   |   |   |   |   |   |   |
| Cost of revenue                                |   |                                   | 263,041 |   |   |   | 241,033 |   |
|                                           |   |                                   |   |   |   |   |   |   |
| Gross margin                                   |   |                                   | 116,332 |   |   |   | 380,833 |   |
|                                           |   |                                   |   |   |   |   |   |   |
| Operating expenses:                            |   |                                   |   |   |   |   |   |   |
| Sales and marketing                            |   |                                   | 601,245 |   |   |   | 1,179,791 |   |
| Research and development                       |   |                                   | 5,142,083 |   |   |   | 4,628,262 |   |
| General and administrative                     |   |                                   | 4,383,082 |   |   |   | 2,603,180 |   |
|                                           |   |                                   |   |   |   |   |   |   |
| Total operating expenses                       |   |                                   | 10,126,410 |   |   |   | 8,411,233 |   |
|                                           |   |                                   |   |   |   |   |   |   |
| Operating loss                                 |   |                                   | (10,010,078 | ) |   |   | (8,030,400 | ) |
|                                           |   |                                   |   |   |   |   |   |   |
| Other income and (expenses):                   |   |                                   |   |   |   |   |   |   |
| Interest income                                |   |                                   | 14,493 |   |   |   | 82,318 |   |
| Interest expense                               |   |                                   | (9,570 | ) |   |   | (14,851 | ) |
| Unrealized loss on fair value of warrants, net |   |                                   | (564,122 | ) |   |   | — |   |
| Miscellaneous expense                          |   |                                   | (51,211 | ) |   |   | (78,504 | ) |
|                                           |   |                                   |   |   |   |   |   |   |
| Total other income (expense)                   |   |                                   | (610,410 | ) |   |   | (11,037 | ) |
|                                           |   |                                   |   |   |   |   |   |   |
| Net loss before provision for income taxes     |   |                                   | (10,620,488 | ) |   |   | (8,041,437 | ) |
|                                           |   |                                   |   |   |   |   |   |   |
| Provision for income taxes                     |   |                                   | — |   |   |   | — |   |
|                                           |   |                                   |   |   |   |   |   |   |
| Net loss                                       |   | $                                      | (10,620,488 | ) |   | $ | (8,041,437 | ) |

| Year Ended December 31, |   |
|----------------------------------------|--------|
| 2009                                   |   |   | 2008 |   |   | % Change |   |
|                                   |   |   |   |   |   |   |   |   |
|                                   | $      | 379,373 |   |   | $ | 621,866 |   |   |   | (38.99 | )% |

| Year Ended December 31, |   |
|----------------------------------------|--------|
| 2009                                   |   |   | 2008 |   |   | % Change |   |
|                                   |   |   |   |   |   |   |   |   |
|                                   | $      | 263,041 |   |   | $ | 241,033 |   |   |   | 9.13 | % |

----

| Year Ended December 31, |   |
|----------------------------------------|--------|
| 2009                                   |   |   | 2008 |   |   | % Change |   |
|                                   |   |   |   |   |   |   |   |   |
|                                   | $      | 601,245 |   |   | $ | 1,179,791 |   |   |   | (49.04 | )% |

| Year Ended December 31, |   |
|----------------------------------------|--------|
| 2009                                   |   |   | 2008 |   |   | % Change |   |
|                                   |   |   |   |   |   |   |   |   |
|                                   | $      | 5,142,083 |   |   | $ | 4,628,262 |   |   |   | 11.10 | % |

| Year Ended December 31, |   |
|----------------------------------------|--------|
| 2009                                   |   |   | 2008 |   |   | % Change |   |
|                                   |   |   |   |   |   |   |   |   |
|                                   | $      | 4,383,082 |   |   | $ | 2,603,180 |   |   |   | 68.37 | % |

----

| Year Ended December 31, |   |
|----------------------------------------|--------|
| 2009                                   |   |   | 2008 |   |   | % Change |   |
|                                   |   |   |   |   |   |   |   |   |
|                                   | $      | 14,493 |   |   | $ | 82,318 |   |   |   | (82.39 | )% |

| Year Ended December 31, |   |
|----------------------------------------|--------|
| 2009                                   |   |   | 2008 |   |   | % Change |   |
|                                   |   |   |   |   |   |   |   |   |
|                                   | $      | 9,570 |   |   | $ | 14,851 |   |   |   | (35.56 | )% |

| Year Ended December 31, |   |
|----------------------------------------|--------|
| 2009                                   |   |   | 2008 |   |   | % Change |   |
|                                   |   |   |   |   |   |   |   |   |
|                                   | $      | 564,122 |   |   | $ | — |   |   |   | N/A | % |

----

| Year Ended December 31, |   |
|----------------------------------------|--------|
| 2009                                   |   |   | 2008 |   |   | % Change |   |
|                                   |   |   |   |   |   |   |   |   |
|                                   | $      | 51,211 |   |   | $ | 78,504 |   |   |   | (34.77 | )% |

----

----

|                    |   |   | December 31, 2009 |   |   | December 31, 2008 |   |
|-------------------------|--------|--------|-----------------------------|--------|--------|-----------------------------|--------|
|                    |   |   |                        |   |   |                        |   |
| Risk-free interest rate |   |   | 1.31% - 2.97%               |   |   | 2.37% - 3.34%               |   |
|                    |   |   |                        |   |   |                        |   |
| Expected term           |   |   | 4.75 Years                  |   |   | 4.75 – 5.00 Years     |   |
|                    |   |   |                        |   |   |                        |   |
| Expected volatility     |   |   | 40.04% - 42.44%             |   |   | 16.97% - 33.31%             |   |
|                    |   |   |                        |   |   |                        |   |
| Dividend yield          |   |   | 0%                          |   |   | 0%                          |   |

----

|                                      |   | December 31, 2009 |   |
|-------------------------------------------|--------|-----------------------------|--------|
|                                      |   |                        |   |
| Risk-free interest rate                   |   | 1.16% - 2.16%               |   |
|                                      |   |                        |   |
| Expected remaining term                   |   | 2.71 - 4.00 Years           |   |
|                                      |   |                        |   |
| Expected volatility                       |   | 43.26% - 49.78%             |   |
|                                      |   |                        |   |
| Dividend yield                            |   | 0%                          |   |
|                                      |   |                        |   |
| Private Placement discount to stock price |   | 15%                         |   |

----

----

| Index to Consolidated Financial Statements                                                   |   |   | Page   |
|----------------------------------------------------------------------------------------------|--------|--------|--------|
|                                                                                         |   |   |   |
| Report of Independent Registered Public Accounting Firm                                      |   |   | 12     |
|                                                                                         |   |   |   |
| Consolidated Balance Sheets                                                                  |   |   | 13     |
|                                                                                         |   |   |   |
| Consolidated Statements of Operations                                                        |   |   | 14     |
|                                                                                         |   |   |   |
| Consolidated Statements of Series B Preferred Stock and Stockholders’ Equity (Deficit) |   |   | 15     |
|                                                                                         |   |   |   |
| Consolidated Statements Stockholders’ Equity (Deficit) and Comprehensive Income (Loss) |   |   | 18     |
|                                                                                         |   |   |   |
| Consolidated Statements of Cash Flows                                                        |   |   | 20     |
|                                                                                         |   |   |   |
| Notes to the Consolidated Financial Statements                                               |   |   | 21     |

----

----

|                                                                                                                                                                        |   | December 31, 2009         |        |    | December 31, 2008 |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------|-------------|---------|-----------------------------|--------|
|                                                                                                                                                                        |   | (As restated,See Note 16) |        |    |                        |   |
| Assets                                                                                                                                                                      |   |                                |        |    |                        |   |
| Current assets:                                                                                                                                                             |   |                                |        |    |                        |   |
| Cash and cash equivalents                                                                                                                                                   |   | $                                   | 5,953,639   |    |                        | $      | 2,597,413 |   |
| Accounts receivable                                                                                                                                                         |   |                                | 258,855     |    |                        |   | 40,757 |   |
| Inventories, net                                                                                                                                                            |   |                                | 39,970      |    |                        |   | 227,272 |   |
| Prepaid expenses and other current assets                                                                                                                                   |   |                                | 138,712     |    |                        |   | 135,629 |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Total current assets                                                                                                                                                        |   |                                | 6,391,176   |    |                        |   | 3,001,071 |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Property and equipment, net                                                                                                                                                 |   |                                | 441,996     |    |                        |   | 795,339 |   |
| Other assets                                                                                                                                                                |   |                                | 57,982      |    |                        |   | 15,690 |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Total assets                                                                                                                                                                |   | $                                   | 6,891,154   |    |                        | $      | 3,812,100 |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Liabilities and Stockholders’ Equity (Deficit)                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Current liabilities:                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Accounts payable                                                                                                                                                            |   | $                                   | 1,240,397   |    |                        | $      | 904,094 |   |
| Accrued rent                                                                                                                                                                |   |                                | 10,493      |    |                        |   | 31,671 |   |
| Accrued payroll                                                                                                                                                             |   |                                | 241,586     |    |                        |   | 160,242 |   |
| Accrued severance pay                                                                                                                                                       |   |                                | 371,596     |    |                        |   | — |   |
| Accrued vacation                                                                                                                                                            |   |                                | 117,619     |    |                        |   | 181,377 |   |
| Accrued other expenses                                                                                                                                                      |   |                                | 157,699     |    |                        |   | 72,012 |   |
| Current portion of capital lease obligations                                                                                                                                |   |                                | 21,663      |    |                        |   | 55,934 |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Total current liabilities                                                                                                                                                   |   |                                | 2,161,053   |    |                        |   | 1,405,330 |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Capital lease obligations, net of current portion                                                                                                                           |   |                                | 8,852       |    |                        |   | 24,928 |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Warrant derivative liability                                                                                                                                                |   |                                | 2,778,191   |    |                        |   | — |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Redeemable convertible preference shares in subsidiary                                                                                                                      |   |                                | 3,290,994   |    |                        |   | 1,977,916 |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Commitments and contingencies                                                                                                                                               |   |                                | —     |    |                        |   | — |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Stockholders’ equity (deficit):                                                                                                                                       |   |                                |        |    |                        |   |   |   |
| Preferred Stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding                                                                           |   |                                | —     |    |                        |   | — |   |
| Common Stock: $0.001 par value; 300,000,000 shares authorized; 33,387,857 and 24,830,932 shares issued and outstanding at December 31, 2009 and December 31, 2008 |   |                                | 33,388      |    |                        |   | 24,831 |   |
| Additional paid-in capital                                                                                                                                                  |   |                                | 29,017,578  |    |                        |   | 20,397,789 |   |
| Accumulated deficit                                                                                                                                                         |   |                                | (30,462,283 | )       |                        |   | (20,032,260 | ) |
| Accumulated other comprehensive income                                                                                                                                      |   |                                | 63,381      |    |                        |   | 13,566 |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Total stockholders’ equity (deficit)                                                                                                                                  |   |                                | (1,347,936  | )  |                        |   | 403,926 |   |
|                                                                                                                                                                        |   |                                |        |    |                        |   |   |   |
| Total liabilities and stockholders’ equity (deficit)                                                                                                                  |   | $                                   | 6,891,154   |    |                        | $      | 3,812,100 |   |

----

|                                                                |   | Year Ended December 31, |        |   | Period From October 22, 2002(Inception) to |   |
|---------------------------------------------------------------------|--------|----------------------------------------|-------------|--------|----------------------------------------------------------------|--------|
|                                                                |   | 2009                                   |        |   | 2008                                                           |   |   | December 31, 2009 |   |
|                                                                |   | (As restated,See Note 16)    |        |   |                                                           |   |   | (As restated,See Note 16) |   |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |
| Revenue                                                             |   | $                                      | 379,373     |   |                                                           | $      | 621,866 |   |   | $ | 1,295,507 |   |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Cost of revenue                                                     |   |                                   | 263,041     |   |                                                           |   | 241,033 |   |   |   | 604,940 |   |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Gross margin                                                        |   |                                   | 116,332     |   |                                                           |   | 380,833 |   |   |   | 690,567 |   |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Operating expenses:                                                 |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Sales and marketing                                                 |   |                                   | 601,245     |   |                                                           |   | 1,179,791 |   |   |   | 2,782,259 |   |
| Research and development                                            |   |                                   | 5,142,083   |   |                                                           |   | 4,628,262 |   |   |   | 15,838,473 |   |
| General and administrative                                          |   |                                   | 4,383,082   |   |                                                           |   | 2,603,180 |   |   |   | 11,773,236 |   |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Total operating expenses                                            |   |                                   | 10,126,410  |   |                                                           |   | 8,411,233 |   |   |   | 30,393,968 |   |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Operating loss                                                      |   |                                   | (10,010,078 | )      |                                                           |   | (8,030,400 | ) |   |   | (29,703,401 | ) |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Other income and (expenses):                                        |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Interest income                                                     |   |                                   | 14,493      |   |                                                           |   | 82,318 |   |   |   | 259,858 |   |
| Interest expense                                                    |   |                                   | (9,570      | )      |                                                           |   | (14,851 | ) |   |   | (321,454 | ) |
| Unrealized loss on fair value of warrants, net                 |   |                                   | (564,122    | )      |                                                           |   | — |   |   |   | (564,122 | ) |
| Miscellaneous expense                                               |   |                                   | (51,211     | )      |                                                           |   | (78,504 | ) |   |   | (129,715 | ) |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Total other income and (expenses)                                   |   |                                   | (610,410    | )      |                                                           |   | (11,037 | ) |   |   | (755,433 | ) |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Net loss before provision for income taxes                          |   |                                   | (10,620,488 | )      |                                                           |   | (8,041,437 | ) |   |   | (30,458,834 | ) |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Provision for income taxes                                          |   |                                   | —     |   |                                                           |   | — |   |   |   | — |   |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Net loss                                                            |   |                                   | (10,620,488 | )      |                                                           |   | (8,041,437 | ) |   |   | (30,458,834 | ) |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Cumulative effect of reclassification of warrants                   |   |                                   | —     |   |                                                           |   | — |   |   |   | 368,627 |   |
| Accretion on Redeemable Convertible Preference Shares in Subsidiary |   |                                   | (178,162    | )      |                                                           |   | (37,916 | ) |   |   | (216,078 | ) |
| Accretion on Series B Preferred Stock                               |   |                                   | —     |   |                                                           |   | — |   |   |   | (155,998 | ) |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Net loss applicable to common stockholders                          |   | $                                      | (10,798,650 | )      |                                                           | $      | (8,079,353 | ) |   | $ | (30,462,283 | ) |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Net loss per share - basic and diluted                              |   | $                                      | (0.39       | )      |                                                           | $      | (0.33 | ) |   |   |   |   |
|                                                                |   |                                   |        |   |                                                           |   |   |   |   |   |   |   |
| Shares used to compute net loss per share - basic and diluted       |   |                                   | 27,378,293  |   |                                                           |   | 24,214,807 |   |   |   |   |   |

----

|                                                                                                                                                    | Series B        |   | Series A        |    |         | Additional |        |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|--------|-----------------|---------|--------------|------------|-------------|--------|
|                                                                                                                                                    | Preferred Stock |   | Preferred Stock |    | Common Stock | Paid-in    | Accumulated |   |
|                                                                                                                                                    | Shares          |   | Amount          |    | Shares       |       | Amount      |   | Shares | Amount | Capital | Deficit | Total |
|                                                                                                                                                    |            |   |            |    |         |       |        |   |   |   |   |   |   |
| Balances as of October 22, 2002                                                                                                               | —         |   | $               | — |         | —    |        | $      | — |   | — | $ | — | $ | — | $ | — | $ | — |
|                                                                                                                                                    |            |   |            |    |         |       |        |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss                                                                                                                                                | —         |   |            | — |         | —    |        |   | — |   | — |   | — |   | — |   | — |   | — |
|                                                                                                                                                    |            |   |            |    |         |       |        |   |   |   |   |   |   |   |   |   |   |   |   |
|        Balances as of             December 31, 2002 | —         |   | $               | — |         | —    |        | $      | — |   | — | $ | — | $ | — | $ | — | $ | — |

|                                                                                                                                                    | Series B        |   | Series A        |    |         | Additional |        |   |    |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|--------|-----------------|---------|--------------|------------|-------------|--------|---------|--------|
|                                                                                                                                                    | Preferred Stock |   | Preferred Stock |    | Common Stock | Paid-in    | Accumulated |   |    |   |
|                                                                                                                                                    | Shares          |   | Amount          |    | Shares       |       | Amount      |   | Shares  | Amount | Capital | Deficit |   | Total |   |
|                                                                                                                                                    |            |   |            |    |         |       |        |   |    |   |   |   |   |   |   |
| Balances as of January 1, 2003                                                                                                                | —         |   | $               | — |         | —    |        | $      | — |   | — | $ | — | $ | — | $ | — |   | $ | — |   |
|                                                                                                                                                    |            |   |            |    |         |       |        |   |    |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss                                                                                                                                                | —         |   |            | — |         | —    |        |   | — |   | — |   | — |   | — |   | (533,985 | ) |   | (533,985 | ) |
|                                                                                                                                                    |            |   |            |    |         |       |        |   |    |   |   |   |   |   |   |   |   |   |   |   |   |
|        Balances as of             December 31, 2003 | —         |   | $               | — |         | —    |        | $      | — |   | — | $ | — | $ | — | $ | (533,985 | ) | $ | (533,985 | ) |

|                                                                                                                                                    | Series B        |   | Series A        |    |         | Additional |   |        |    |   |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|--------|-----------------|---------|--------------|------------|--------|-------------|---------|--------|-----------|
|                                                                                                                                                    | Preferred Stock |   | Preferred Stock |    | Common Stock | Paid-in    |   | Accumulated |    |   |      |
|                                                                                                                                                    | Shares          |   | Amount          |    | Shares       |       | Amount |        | Shares  | Amount | Capital   |   | Deficit |   | Total |   |
|                                                                                                                                                    |            |   |            |    |         |       |   |        |    |   |      |   |   |   |   |   |
| Balances as of January 1, 2004                                                                                                                | —         |   | $               | — |         | —    |   | $           | — |   | —   | $ | — | $ | — |   | $ | (533,985 | ) | $ | (533,985 | ) |
|                                                                                                                                                    |            |   |            |    |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock in June for cash                                                                                                               | —         |   |            | — |         | —    |   |        | — |   | 2,483,610 |   | 2,484 |   | (2,024 | )  |   | — |   |   | 460 |   |
|                                                                                                                                                    |            |   |            |    |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Stock-based compensation                                                                                                                                | —         |   |            | — |         | —    |   |        | — |   | —   |   | — |   | 1,242 |   |   | — |   |   | 1,242 |   |
|                                                                                                                                                    |            |   |            |    |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Net loss                                                                                                                                                | —         |   |            | — |         | —    |   |        | — |   | —   |   | — |   | — |   |   | (1,124,360 | ) |   | (1,124,360 | ) |
|                                                                                                                                                    |            |   |            |    |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
|        Balances as of             December 31, 2004 | —         |   | $               | — |         | —    |   | $           | — |   | 2,483,610 | $ | 2,484 | $ | (782 | )  | $ | (1,658,345 | ) | $ | (1,656,643 | ) |

----

|                                                                                                                                                    | Series B        |   | Series A        |    |         | Additional |   |        |    |   |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|--------|-----------------|---------|--------------|------------|--------|-------------|---------|--------|-----------|
|                                                                                                                                                    | Preferred Stock |   | Preferred Stock |    | Common Stock | Paid-in    |   | Accumulated |    |   |      |
|                                                                                                                                                    | Shares          |   | Amount          |    | Shares       |       | Amount |        | Shares  | Amount | Capital   |   | Deficit |   | Total |   |
|                                                                                                                                                    |            |   |            |    |         |       |   |        |    |   |      |   |   |   |   |   |
| Balances as of January 1, 2005                                                                                                                | —         |   | $               | — |         | —    |   | $           | — |   | 2,483,610 | $ | 2,484 | $ | (782 | ) | $ | (1,658,345) |   | $ | (1,656,643 | ) |
|                                                                                                                                                    |            |   |            |    |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Series A Preferred Stock in February upon conversion of notes payable and accrued interest                                                  | —         |   |            | — |         | 5,915,219  |   |        | 592     |   | —   |   | — |   | 3,134,481 |   |   | — |   |   | 3,135,073 |   |
|                                                                                                                                                    |            |   |            |    |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock in September for cash                                                                                                          | —         |   |            | — |         | —    |   |        | — |   | 917,856   |   | 918 |   | (748 | ) |   | — |   |   | 170 |   |
|                                                                                                                                                    |            |   |            |    |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Stock-based compensation                                                                                                                                | —         |   |            | — |         | —    |   |        | — |   | —   |   | — |   | 8,575 |   |   | — |   |   | 8,575 |   |
|                                                                                                                                                    |            |   |            |    |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Net loss                                                                                                                                                | —         |   |            | — |         | —    |   |        | — |   | —   |   | — |   | — |   |   | (1,494,449 | ) |   | (1,494,449 | ) |
|                                                                                                                                                    |            |   |            |    |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
|        Balances as of             December 31, 2005 | —         |   | $               | — |         | 5,915,219  |   | $           | 592     |   | 3,401,466 | $ | 3,402 | $ | 3,141,526 |   | $ | (3,152,794 | ) | $ | (7,274 | )  |

|                                                                                                                                          | Series B        |   | Series A        |      |         | Additional |   |        |    |   |      |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------|--------|-----------------|-----------|--------------|------------|--------|-------------|---------|--------|-----------|
|                                                                                                                                          | Preferred Stock |   | Preferred Stock |      | Common Stock | Paid-in    |   | Accumulated |    |   |      |
|                                                                                                                                          | Shares          |   | Amount          |      | Shares       |       | Amount |        | Shares  | Amount | Capital   |   | Deficit |   | Total |   |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |
| Balances as of January 1, 2006                                                                                                      | —         |   | $               | —   |         | 5,915,219  |   | $           | 592     |   | 3,401,466 | $ | 3,402 | $ | 3,141,526 |   | $ | (3,152,794 | ) | $ | (7,274 | ) |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock in January for cash                                                                                                  | —         |   |            | —   |         | —    |   |        | — |   | 4,049     |   | 4 |   | (3 | ) |   | — |   |   | 1 |   |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Series B Preferred Stock in February for cash                                                                                     | 2,052,552       |   |            | 1,559,942 |         | —    |   |        | — |   | —   |   | — |   | — |   |   | — |   |   | — |   |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of restricted shares in March for services                                                                                           | —         |   |            | —   |         | —    |   |        | — |   | 24,296    |   | 24 |   | (24 | ) |   | — |   |   | — |   |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock in June for cash                                                                                                     | —         |   |            | —   |         | —    |   |        | — |   | 8,099     |   | 8 |   | (7 | ) |   | — |   |   | 1 |   |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of restricted shares in July for services                                                                                            | —         |   |            | —   |         | —    |   |        | — |   | 10,798    |   | 11 |   | (11 | ) |   | — |   |   | — |   |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of restricted shares in August for services                                                                                          | —         |   |            | —   |         | —    |   |        | — |   | 16,197    |   | 16 |   | (16 | ) |   | — |   |   | — |   |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock in August for cash                                                                                                   | —         |   |            | —   |         | —    |   |        | — |   | 17,007    |   | 17 |   | (14 | ) |   | — |   |   | 3 |   |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Accretions on Series B Preferred Stock                                                                                                        | —         |   |            | 104,000   |         | —    |   |        | — |   | —   |   | — |   | — |   |   | (104,000 | ) |   | (104,000 | ) |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of restricted shares in November for services                                                                                        | —         |   |            | —   |         | —    |   |        | — |   | 5,399     |   | 5 |   | (5 | ) |   | — |   |   | — |   |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock in November for cash                                                                                                 | —         |   |            | —   |         | —    |   |        | — |   | 8,639     |   | 9 |   | (7 | ) |   | — |   |   | 2 |   |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Stock-based compensation                                                                                                                      | —         |   |            | —   |         | —    |   |        | — |   | —   |   | — |   | 642,076 |   |   | — |   |   | 642,076 |   |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
| Net loss                                                                                                                                      | —         |   |            | —   |         | —    |   |        | — |   | —   |   | — |   | — |   |   | (2,686,451 | ) |   | (2,686,451 | ) |
|                                                                                                                                          |            |   |            |      |         |       |   |        |    |   |      |   |   |   |   |   |   |   |   |   |   |   |
|        Balances as of             December 31, 2006 | 2,052,552       |   | $               | 1,663,942 |         | 5,915,219  |   | $           | 592     |   | 3,495,950 | $ | 3,496 | $ | 3,783,515 |   | $ | (5,943,245 | ) | $ | (2,155,642 | ) |

----

|                                                                                                  |   | Series B        |       |   | Series A        |   |       |         |   |   | Additional |   |   |        |    |   |   |   |
|-------------------------------------------------------------------------------------------------------|--------|-----------------|------------|--------|-----------------|--------|------------|--------------|--------|--------|------------|--------|--------|-------------|---------|--------|--------|--------|
|                                                                                                  |   | Preferred Stock |       |   | Preferred Stock |   |       | Common Stock |   |   | Paid-in    |   |   | Accumulated |    |   |   |   |
|                                                                                                  |   | Shares          |       |   | Amount          |   |       | Shares       |   |   | Amount     |   |   | Shares      |    |   | Amount |   |   | Capital |   |   | Deficit |   |   | Total |   |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |
| Balances as of        January 1, 2007                         |   |            | 2,052,552  |   |            | $      | 1,663,942  |         |   |   | 5,915,219  |   |   | $           | 592     |   |   |   | 3,495,950 |   |   | $ | 3,496 |   |   | $ | 3,783,515 |   |   | $ | (5,943,245 | ) |   | $ | (2,155,642 | ) |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock in January for cash                                                          |   |            | —    |   |            |   | —    |         |   |   | —    |   |   |        | — |   |   |   | 26,996 |   |   |   | 27 |   |   |   | 473 |   |   |   | — |   |   |   | 500 |   |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of restricted shares in January for services                                                 |   |            | —    |   |            |   | —    |         |   |   | —    |   |   |        | — |   |   |   | 134,979 |   |   |   | 135 |   |   |   | (135 | ) |   |   | — |   |   |   | — |   |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Series A Preferred Stock in February for cash                                             |   |            | —    |   |            |   | —    |         |   |   | 471,698    |   |   |        | 47      |   |   |   | — |   |   |   | — |   |   |   | 65,990 |   |   |   | — |   |   |   | 66,037 |   |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of WaferGen Bio-systems, Inc. Common Stock to WaferGen, Inc.'s Preferred shareholders in May |   |            | (2,052,552 | )      |            |   | (1,715,940 | )            |   |   | (6,386,917 | )      |   |        | (639    | )      |   |   | 4,556,598 |   |   |   | 4,557 |   |   |   | 1,712,022 |   |   |   | — |   |   |   | 1,715,940 |   |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Units for cash and notes payable in May and June, net of offering costs of $1,917,956     |   |            | —    |   |            |   | —    |         |   |   | —    |   |   |        | — |   |   |   | 8,008,448 |   |   |   | 8,008 |   |   |   | 10,086,704 |   |   |   | — |   |   |   | 10,094,712 |   |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| WaferGen Bio-systems, Inc. shares outstanding                                                         |   |            | —    |   |            |   | —    |         |   |   | —    |   |   |        | — |   |   |   | 11,277,782 |   |   |   | 11,278 |   |   |   | (11,278 | ) |   |   | — |   |   |   | — |   |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Common Stock cancelled in May in accordance with Split-Off Agreement                                  |   |            | —    |   |            |   | —    |         |   |   | —    |   |   |        | — |   |   |   | (4,277,778 | ) |   |   | (4,278 | ) |   |   | 4,278 |   |   |   | — |   |   |   | — |   |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of warrants in May and June to a placement agent                                             |   |            | —    |   |            |   | —    |         |   |   | —    |   |   |        | — |   |   |   | — |   |   |   | — |   |   |   | 66,319 |   |   |   | — |   |   |   | 66,319 |   |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of warrants with debt in January, February and March                                         |   |            | —    |   |            |   | —    |         |   |   | —    |   |   |        | — |   |   |   | — |   |   |   | — |   |   |   | 171,053 |   |   |   | — |   |   |   | 171,053 |   |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock-based compensation                                                                              |   |            | —    |   |            |   | —    |         |   |   | —    |   |   |        | — |   |   |   | — |   |   |   | — |   |   |   | 648,988 |   |   |   | — |   |   |   | 648,988 |   |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Accretions on Series B Preferred Stock                                                                |   |            | —    |   |            |   | 51,998     |         |   |   | —    |   |   |        | — |   |   |   | — |   |   |   | — |   |   |   | — |   |   |   | (51,998 | ) |   |   | (51,998 | ) |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Common Stock cancelled in July                                                                        |   |            | —    |   |            |   | —    |         |   |   | —    |   |   |        | — |   |   |   | (5,129 | ) |   |   | (5 | ) |   |   | — |   |   |   | — |   |   |   | (5 | ) |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss                                                                                              |   |            | —    |   |            |   | —    |         |   |   | —    |   |   |        | — |   |   |   | — |   |   |   | — |   |   |   | — |   |   |   | (5,957,664 | ) |   |   | (5,957,664 | ) |
|                                                                                                  |   |            |       |   |            |   |       |         |   |   |       |   |   |        |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balances as ofDecember 31, 2007                                                             |   |            | —    |   |            | $      | —    |         |   |   | —    |   |   | $           | — |   |   |   | 23,217,846 |   |   | $ | 23,218 |   |   | $ | 16,527,929 |   |   | $ | (11,952,907 | ) |   | $ | 4,598,240 |   |

----

|                                                                |            |   |         |    |    |       |        |   |          |   | Accumulated |       |   |   |
|---------------------------------------------------------------------|-----------------|--------|--------------|---------|---------|------------|-------------|--------|---------------|--------|-------------|------------|--------|--------|
|                                                                |            |   |         |    |    |       | Additional  |   |          |   | Other       |       |   |   |
|                                                                | Preferred Stock |   | Common Stock |    | Paid-in |       | Accumulated |   | Comprehensive |   |        |       |
|                                                                | Shares          |   | Amount       |    | Shares  |       | Amount      |   | Capital       |   | Deficit     |       | Income |   | Total |   |
|                                                                |            |   |         |    |    |       |        |   |          |   |        |       |   |   |   |   |   |   |   |   |   |   |
| Balances as of January 1, 2008                            | —         |   | $            | — |    | 23,217,846 |        | $      | 23,218        |   | $           | 16,527,929 |   | $      | (11,952,907 | ) | $ | — |   | $ | 4,598,240 |   |
|                                                                |            |   |         |    |    |       |        |   |          |   |        |       |   |   |   |   |   |   |   |   |   |   |
| Issuance of Units for cash in May, net of offering costs of $88,743 | —         |   |         | — |    | 1,585,550  |        |   | 1,586         |   |        | 3,477,158  |   |   | — |   |   | — |   |   | 3,478,744 |   |
|                                                                |            |   |         |    |    |       |        |   |          |   |        |       |   |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock in May for cash                            | —         |   |         | — |    | 27,536     |        |   | 27            |   |        | 4,052      |   |   | — |   |   | — |   |   | 4,079 |   |
|                                                                |            |   |         |    |    |       |        |   |          |   |        |       |   |   |   |   |   |   |   |   |   |   |
| Stock-based compensation                                            | —         |   |         | — |    | —    |        |   | —       |   |        | 388,650    |   |   | — |   |   | — |   |   | 388,650 |   |
|                                                                |            |   |         |    |    |       |        |   |          |   |        |       |   |   |   |   |   |   |   |   |   |   |
| Net loss                                                            | —         |   |         | — |    | —    |        |   | —       |   |        | —    |   |   | (8,041,437 | ) |   | — |   |   | (8,041,437 | ) |
|                                                                |            |   |         |    |    |       |        |   |          |   |        |       |   |   |   |   |   |   |   |   |   |   |
| Accretion on Redeemable Convertible Preference Shares in Subsidiary | —         |   |         | — |    | —    |        |   | —       |   |        | —    |   |   | (37,916 | ) |   | — |   |   | (37,916 | ) |
|                                                                |            |   |         |    |    |       |        |   |          |   |        |       |   |   |   |   |   |   |   |   |   |   |
| Translation adjustment                                              | —         |   |         | — |    | —    |        |   | —       |   |        | —    |   |   | — |   |   | 13,566 |   |   | 13,566 |   |
|                                                                |            |   |         |    |    |       |        |   |          |   |        |       |   |   |   |   |   |   |   |   |   |   |
| Balances as of December 31, 2008                          | —         |   | $            | — |    | 24,830,932 |        | $      | 24,831        |   | $           | 20,397,789 |   | $      | (20,032,260 | ) | $ | 13,566 |   | $ | 403,926 |   |
|                                                                |            |   |         |    |    |       |        |   |          |   |        |       |   |   |   |   |   |   |   |   |   |   |
| Total comprehensive income (loss)                                   |            |   |         |    |    |       |        |   |          |   |        |       |   | $      | (8,041,437 | ) | $ | 13,566 |   | $ | (8,027,871 | ) |

----

|                                                                               |            |   |         |           |       |       |        |   |          |   | Accumulated                    |       |                           |   |
|------------------------------------------------------------------------------------|-----------------|--------|--------------|----------------|------------|------------|-------------|--------|---------------|--------|--------------------------------|------------|--------------------------------|--------|
|                                                                               |            |   |         |           | Additional |       |        |   | Other         |   |                           |       |
|                                                                               | Preferred Stock |   | Common Stock |           | Paid-in    |       | Accumulated |   | Comprehensive |   |                           |       |
|                                                                               | Shares          |   | Amount       |           | Shares     |       | Amount      |   | Capital       |   | Deficit                        |       | Income                         |   | Total |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   | (As restated,See Note 16) |       | (As restated,See Note 16) |   |   |   | (As restated,See Note 16) |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Balances as of January 1, 2009                                           | —         |   | $            | —        |       | 24,830,932 |        | $      | 24,831        |   | $                              | 20,397,789 |                           | $      | (20,032,260 | ) | $ | 13,566 |   | $ | 403,926 |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Cumulative effect of reclassification of warrants                                  | —         |   |         | —        |       | —    |        |   | —       |   |                           | (468,071   | )                              |   | 368,627 |   |   | — |   |   | (99,444 | ) |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
|     Balances as of January 1, 2009, as adjusted      |   —  |   |         |   — |       | 24,830,932 |        |   | 24,831        |   |                           | 19,929,718 |                           |   | (19,663,633 | ) |   | 13,566 |   |   | 304,482 |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock in June for cash upon exercise of warrants                | —         |   |         | —        |       | 71,041     |        |   | 71            |   |                           | 100,097    |                           |   | — |   |   | — |   |   | 100,168 |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Issuance of Units for cash in June and August, net of offering costs of $781,122   | —         |   |         | —        |       | 5,009,000  |        |   | 5,009         |   |                           | 4,489,117  |                           |   | — |   |   | — |   |   | 4,494,126 |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Common Stock cancelled in June                                                     | —         |   |         | —        |       | (266       | )           |   | —       |   |                           | —    |                           |   | — |   |   | — |   |   | — |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock in August, net of 4 shares forfeited in cashless exercise | —         |   |         | —        |       | 10,794     |        |   | 11            |   |                           | (9         | )                              |   | — |   |   | — |   |   | 2 |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Restricted Stock issued in July, August, September, October, November and December | —         |   |         | —        |       | 130,000    |        |   | 130           |   |                           | (130       | )                              |   | — |   |   | — |   |   | — |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Issuance of Units for cash in December, net of offering costs of $534,028          | —         |   |         | —        |       | 3,308,335  |        |   | 3,308         |   |                           | 3,582,802  |                           |   | — |   |   | — |   |   | 3,586,110 |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Issuance of warrants in December for services                                      | —         |   |         | —        |       | —    |        |   | —       |   |                           | 37,085     |                           |   | — |   |   | — |   |   | 37,085 |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Issuance of Common Stock in December for cash                                      | —         |   |         | —        |       | 28,021     |        |   | 28            |   |                           | 39,946     |                           |   | — |   |   | — |   |   | 39,974 |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Stock-based compensation                                                           | —         |   |         | —        |       | —    |        |   | —       |   |                           | 838,952    |                           |   | — |   |   | — |   |   | 838,952 |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Net loss                                                                           | —         |   |         | —        |       | —    |        |   | —       |   |                           | —    |                           |   | (10,620,488 | ) |   | — |   |   | (10,620,488 | ) |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Accretion on Redeemable Convertible Preference Shares in Subsidiary                | —         |   |         | —        |       | —    |        |   | —       |   |                           | —    |                           |   | (178,162 | ) |   | — |   |   | (178,162 | ) |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Translation adjustment                                                             | —         |   |         | —        |       | —    |        |   | —       |   |                           | —    |                           |   | — |   |   | 49,815 |   |   | 49,815 |   |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Balances as of December 31, 2009 (as restated)                           | —         |   | $            | —        |       | 33,387,857 |        | $      | 33,388        |   | $                              | 29,017,578 |                           | $      | (30,462,283 | ) | $ | 63,381 |   | $ | (1,347,936 | ) |
|                                                                               |            |   |         |           |       |       |        |   |          |   |                           |       |                           |   |   |   |   |   |   |   |   |   |
| Total comprehensive income (loss) (as restated)                                    |            |   |         |           |       |       |        |   |          |   |                           |       |                           | $      | (10,620,488 | ) | $ | 49,815 |   | $ | (10,570,673 | ) |

----

|                                                                                 |   |                                     |        |   | Period From           |   |
|--------------------------------------------------------------------------------------|--------|------------------------------------------|-------------|--------|----------------------------|--------|
|                                                                                 |   |                                     |        |   | October 22, 2002 |   |
|                                                                                 |   | Year Ended December 31,   |        |   | (Inception) to        |   |
|                                                                                 |   | 2009                                     |        |   | 2008                       |   |   | December 31, 2009 |   |
|                                                                                 |   | (As restated,See Note 16) |        |   |                       |   |   | (As restated,See Note 16) |   |
| Cash flows from operating activities:                                                |   |                                     |        |   |                       |   |   |   |   |
| Net loss                                                                             |   | $                                        | (10,620,488 | )      |                       | $      | (8,041,437 | ) |   | $ | (30,458,834 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities:          |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Depreciation and amortization                                                        |   |                                     | 493,112     |   |                       |   | 294,249 |   |   |   | 913,660 |   |
| Non cash miscellaneous income                                                        |   |                                     | —     |   |                       |   | — |   |   |   | (5 | ) |
| Stock-based compensation                                                             |   |                                     | 838,952     |   |                       |   | 388,650 |   |   |   | 2,528,483 |   |
| Issuance of warrants for services                                                    |   |                                     | 37,085      |   |                       |   | — |   |   |   | 37,085 |   |
| Unrealized loss on fair value of warrants, net                                  |   |                                     | 564,122     |   |                       |   | — |   |   |   | 564,122 |   |
| Exchange loss on issuance of Redeemable Convertible Preference Shares in Subsidiary  |   |                                     | 18,029      |   |                       |   | — |   |   |   | 18,029 |   |
| Provision for excess and obsolete inventory                                          |   |                                     | 130,478     |   |                       |   | — |   |   |   | 130,478 |   |
| Equipment expensed as research & development costs                               |   |                                     | 123,998     |   |                       |   | — |   |   |   | 123,998 |   |
| Issuance of Series A Preferred Stock for legal services                              |   |                                     | —     |   |                       |   | — |   |   |   | 50,000 |   |
| Issuance of Series A Preferred Stock for interest owed                               |   |                                     | —     |   |                       |   | — |   |   |   | 107,494 |   |
| Amortization of debt discount                                                        |   |                                     | —     |   |                       |   | — |   |   |   | 171,053 |   |
| Change in operating assets and liabilities:                                          |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Accounts receivable                                                                  |   |                                     | (218,098    | )      |                       |   | 99,070 |   |   |   | (258,855 | ) |
| Inventories                                                                          |   |                                     | 56,824      |   |                       |   | (164,751 | ) |   |   | (170,448 | ) |
| Prepaid expenses and other current assets                                            |   |                                     | (3,012      | )      |                       |   | (48,206 | ) |   |   | (138,705 | ) |
| Other assets                                                                         |   |                                     | (42,209     | )      |                       |   | (13,225 | ) |   |   | (58,004 | ) |
| Accounts payable                                                                     |   |                                     | 337,363     |   |                       |   | 344,804 |   |   |   | 1,242,808 |   |
| Accrued rent                                                                         |   |                                     | (21,135     | )      |                       |   | 12,729 |   |   |   | 10,934 |   |
| Accrued payroll                                                                      |   |                                     | 81,344      |   |                       |   | (254,277 | ) |   |   | 241,586 |   |
| Accrued severance pay                                                                |   |                                     | 371,596     |   |                       |   | — |   |   |   | 371,596 |   |
| Accrued vacation                                                                     |   |                                     | (63,911     | )      |                       |   | 25,255 |   |   |   | 117,578 |   |
| Accrued other expenses                                                               |   |                                     | 83,618      |   |                       |   | 72,959 |   |   |   | 156,577 |   |
| Net cash used in operating activities                                                |   |                                     | (7,832,332  | )      |                       |   | (7,284,180 | ) |   |   | (24,299,370 | ) |
|                                                                                 |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Cash flows from investing activities:                                                |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Purchase of property and equipment                                                   |   |                                     | (263,291    | )      |                       |   | (601,897 | ) |   |   | (1,239,316 | ) |
|                                                                                 |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Net cash used in investing activities                                                |   |                                     | (263,291    | )      |                       |   | (601,897 | ) |   |   | (1,239,316 | ) |
|                                                                                 |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Cash flows from financing activities:                                                |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Advances from (repayments to) related party, net                                     |   |                                     | —     |   |                       |   | — |   |   |   | 61,588 |   |
| Repayment of capital lease obligations                                               |   |                                     | (50,347     | )      |                       |   | (145,682 | ) |   |   | (214,911 | ) |
| Proceeds from issuance of notes payable                                              |   |                                     | —     |   |                       |   | — |   |   |   | 3,665,991 |   |
| Net proceeds from issuance of Redeemable Convertible Preference Shares in Subsidiary |   |                                     | 1,116,887   |   |                       |   | 1,940,000 |   |   |   | 3,056,887 |   |
| Repayments on notes payable                                                          |   |                                     | —     |   |                       |   | — |   |   |   | (510,000 | ) |
| Proceeds from issuance of Series A Preferred Stock                                   |   |                                     | —     |   |                       |   | — |   |   |   | 66,037 |   |
| Proceeds from issuance of Series B Preferred Stock                                   |   |                                     | —     |   |                       |   | — |   |   |   | 1,559,942 |   |
| Proceeds from issuance of Common Stock, net of offering costs                        |   |                                     | 10,335,005  |   |                       |   | 3,482,823 |   |   |   | 23,739,996 |   |
|                                                                                 |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Net cash provided by financing activities                                            |   |                                     | 11,401,545  |   |                       |   | 5,277,141 |   |   |   | 31,425,530 |   |
|                                                                                 |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Effect of exchange rates on cash                                                     |   |                                     | 50,304      |   |                       |   | 16,491 |   |   |   | 66,795 |   |
|                                                                                 |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Net increase (decrease) in cash and cash equivalents                                 |   |                                     | 3,356,226   |   |                       |   | (2,592,445 | ) |   |   | 5,953,639 |   |
|                                                                                 |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Cash and cash equivalents at beginning of the period                                 |   |                                     | 2,597,413   |   |                       |   | 5,189,858 |   |   |   | — |   |
|                                                                                 |   |                                     |        |   |                       |   |   |   |   |   |   |   |
| Cash and cash equivalents at end of the period                                       |   | $                                        | 5,953,639   |   |                       | $      | 2,597,413 |   |   | $ | 5,953,639 |   |

----

----

| Gross proceeds from initial offering    |   | $      | 10,767,668       |    |
|-----------------------------------------|--------|--------|------------------|---------|
| Gross proceeds from additional offering |   |   | 1,245,000        |    |
|                                    |   |   |             |    |
| Gross proceeds                          |   |   | 12,012,668       |    |
| Offering costs:                         |   |   |             |    |
| Paid                                    |   |   | (1,851,637  |  ) |
| Issuance of warrants to placement agent |   |   | (66,319          | )       |
|                                    |   |   |             |    |
| Total offering costs                    |   |   | (1,917,956       | )       |
|                                    |   |   |             |    |
| Gross proceeds less offering costs      |   |   | 10,094,712       |    |
| Issuance of warrants to placement agent |   |   | 66,319           |    |
| Cancellation of debt                    |   |   | (240,000         | )       |
|                                    |   |   |             |    |
| Net proceeds                            |   | $      | 9,921,031        |    |

| WaferGen Bio-systems, Inc. shares outstanding prior to the Merger |                     |   | 11,277,782 |       |
|-------------------------------------------------------------------|--------------------------|--------|------------|------------|
| Shares issued to Wafergen, Inc. shareholders                      |                     |   | 8,214,523  |       |
| Shares issued in the Offering                                     |                     |   | 8,008,448  |       |
| Shares cancelled in accordance with the Split-off Agreement       |                     |   | (4,277,778 | )          |
|                                                              |                     |   |       |       |   |
|                                                              | Total shares outstanding |   |       | 23,222,975 |   |

----

| Par value of common stock      |   | $      | 5,009     |   |
|--------------------------------|--------|--------|-----------|--------|
| Paid-in capital                |   |   | 5,270,239 |   |
| Derivative warrant instruments |   |   | 986,002   |   |
|                           |   |   |      |   |
| Total                          |   | $      | 6,261,250 |   |

----

| Par value of common stock      |   | $      | 3,308     |   |
|--------------------------------|--------|--------|-----------|--------|
| Paid-in capital                |   |   | 4,116,884 |   |
| Derivative warrant instruments |   |   | 842,308   |   |
|                           |   |   |      |   |
| Total                          |   | $      | 4,962,500 |   |

----

----

| Equipment              | 3 to 5 years                                     |
|------------------------|--------------------------------------------------|
| Tools and molds        | 3 years                                          |
| Leasehold improvements | 3 to 5 years, or remaining lease term if shorter |
| Furniture and fixtures | 5 years                                          |

----

|   |                    | December 31, 2009 |            | December 31, 2008 |   |
|--------|-------------------------|------------------------|-----------------|------------------------|--------|
|   |                    |                   |            |                   |   |   |   |
|   | Risk-free interest rate |                   | 1.31% - 2.97%   |                   |   | 2.37% - 3.34% |   |
|   |                    |                   |            |                   |   |   |   |
|   | Expected term           |                   | 4.75 Years      |                   |   | 4.75 - 5.00 Years |   |
|   |                    |                   |            |                   |   |   |   |
|   | Expected volatility     |                   | 40.04% - 42.22% |                   |   | 16.97% - 33.31% |   |
|   |                    |                   |            |                   |   |   |   |
|   | Dividend yield          |                   | 0%              |                   |   | 0% |   |

----

|                                                   |                                                                                 |      |            | Year Ended December 31, |          |
|--------------------------------------------------------|--------------------------------------------------------------------------------------|-----------|-----------------|------------------------------|---------------|
|                                                   |                                                                                 |      |            | 2009                         |          | 2008 |   |
|                                                   |                                                                                 |      |            |                         |          |   |   |
| Shares issuable upon exercise of common stock options  |                                                                                 | 1,409,279 |            | 524,954                      |          |
|                                                   |                                                                                 |      |            |                         |          |   |   |
| Shares issuable upon exercise of common stock warrants |                                                                                 | 96,125    |            | —                      |          |
|                                                   |                                                                                 |      |            |                         |          |   |   |
| Shares issuable upon conversion of RCPS                |                                                                                 | 1,095,909 |            | 240,741                      |          |
|                                                   |                                                                                 |      |            |                         |          |   |   |
|                                                   | Total common share equivalents excluded from denominator for diluted EPS computation |      |  2,601,313 |                         |  765,695 |   |

----

|                                             |   | December 31, 2009 |     |   | December 31, 2008 |   |
|--------------------------------------------------|--------|------------------------|----------|--------|------------------------|--------|
|                                             |   |                   |     |   |                   |   |
| Finished goods                                   |   | $                      | 170,448  |   |                   | $      | 227,272 |   |
| Less allowance for excess and obsolete inventory |   |                   | (130,478 | )      |                   |   | — |   |
|                                             |   |                   |     |   |                   |   |   |   |
| Inventories, net                                 |   | $                      | 39,970   |   |                   | $      | 227,272 |   |

|                                           |   | December 31, 2009 |      |   | December 31, 2008 |   |
|------------------------------------------------|--------|------------------------|-----------|--------|------------------------|--------|
|                                           |   |                   |      |   |                   |   |
| Equipment                                      |   | $                      | 1,154,406 |   |                   | $      | 1,014,212 |   |
| Tools and molds                           |   |                   | 72,437    |   |                   |   | 72,437 |   |
| Leasehold improvements                         |   |                   | 63,470    |   |                   |   | 63,163 |   |
| Furniture and fixtures                         |   |                   | 42,570    |   |                   |   | 42,206 |   |
|                                           |   |                   |      |   |                   |   |   |   |
| Total property and equipment                   |   |                   | 1,332,883 |   |                   |   | 1,192,018 |   |
|                                           |   |                   |      |   |                   |   |   |   |
| Less accumulated depreciation and amortization |   |                   | (890,887  | )      |                   |   | (396,679 | ) |
|                                           |   |                   |      |   |                   |   |   |   |
| Property and equipment, net                    |   | $                      | 441,996   |   |                   | $      | 795,339 |   |

----

|                     |   | December 31, 2009 |     |   | December 31, 2008 |   |
|--------------------------|--------|-----------------------------|----------|--------|-----------------------------|--------|
|                     |   |                        |     |
| Cost                     |   | $                           | 178,712  |   |                        | $      | 178,712 |   |
| Accumulated depreciation |   |                        | (168,886 | )      |                        |   | (63,639 | ) |
|                     |   |                        |     |   |                        |   |   |   |
| Total                    |   | $                           | 9,826    |   |                        | $      | 115,073 |   |

|                                             |   | Operating Leases |      |   | Capital Leases |   |
|--------------------------------------------------|--------|------------------|-----------|--------|----------------|--------|
|                                             |   |             |      |   |           |   |
| Year ending December 31,                    |   |             |      |   |           |   |
| 2010                                             |   | $                | 287,207   |   |           | $      | 23,301 |   |
| 2011                                             |   |             | 399,069   |   |           |   | 9,117 |   |
| 2012                                             |   |             | 441,278   |   |           |   | — |   |
| 2013                                             |   |             | 464,301   |   |           |   | — |   |
| 2014                                             |   |             | 487,324   |   |           |   | — |   |
| Thereafter                                       |   |             | 168,837   |   |           |   | — |   |
|                                             |   |             |      |   |           |   |   |   |
| Total minimum lease obligations                  |   | $                | 2,248,016 |   |           |   | 32,418 |   |
|                                             |   |             |      |   |           |   |   |   |
| Less amounts representing interest               |   |             |      |   |           |   | (1,903 | ) |
|                                             |   |             |      |   |           |   |   |   |
| Present value of future minimum lease payments   |   |             |      |   |           |   | 30,515 |   |
|                                             |   |             |      |   |           |   |   |   |
| Less current portion of capital lease obligation |   |             |      |   |           |   | (21,663 | ) |
|                                             |   |             |      |   |           |   |   |   |
| Capital lease obligation, less current portion   |   |             |      |   |           | $      | 8,852 |   |

----

----

|                            |   | December 31, 2009 |      |   | December 31, 2008 |   |
|---------------------------------|--------|------------------------|-----------|--------|------------------------|--------|
| SERIES A                        |   |                   |      |   |                   |   |
| Proceeds from issuance of RCPS  |   | $                      | 2,000,000 |   |                   | $      | 2,000,000 |   |
| Issuance costs                  |   |                   | (60,000   | )      |                   |   | (60,000 | ) |
| Accretion of issuance costs     |   |                   | 25,416    |   |                   |   | 5,416 |   |
| Accretion of redemption premium |   |                   | 154,450   |   |                   |   | 32,500 |   |
|                            |   |                   |      |   |                   |   |   |   |
| Total Series A RCPS             |   |                   | 2,119,866 |   |                   |   | 1,977,916 |   |
|                            |   |                   |      |   |                   |   |   |   |
| SERIES B                        |   |                   |      |   |                   |   |   |   |
| Proceeds from issuance of RCPS  |   |                   | 1,155,099 |   |                   |   | — |   |
| Issuance costs                  |   |                   | (38,212   | )      |                   |   | — |   |
| Exchange loss on issuance       |   |                   | 18,029    |   |                   |   | — |   |
| Accretion of issuance costs     |   |                   | 4,538     |   |                   |   | — |   |
| Accretion of redemption premium |   |                   | 31,674    |   |                   |   | — |   |
|                            |   |                   |      |   |                   |   |   |   |
| Total Series B RCPS             |   |                   | 1,171,128 |   |                   |   | — |   |
|                            |   |                   |      |   |                   |   |   |   |
| Total RCPS                      |   | $                      | 3,290,994 |   |                   | $      | 1,977,916 |   |

----

|                                                      |   |      |       |   | Stock Options |   |      | Restricted Stock |   |
|-----------------------------------------------------------|--------|-----------|------------|--------|---------------|--------|-----------|------------------|--------|
|                                                      |   |      |       |   |          |   |      | Weighted         |   |   |   |   | Weighted |   |
|                                                      |   | Shares    |       |   | Number of     |   |      | Average          |   |   | Number of |   | Average |   |
|                                                      |   | Available |       |   | Options       |   |      | Exercise         |   |   | Options |   | Grant-Date |   |
|                                                      |   | for Grant |       |   | Outstanding   |   |      | Price            |   |   | Outstanding |   | Fair Value |   |
|                                                      |   |      |       |   |          |   |      |             |   |   |   |   |   |   |   |
| Balance at January 1, 2008                           |   |      | 390,500    |   |          |   | 2,268,736 |             |   | $ | 1.3469 |   |   |   | 36,556 |   |   | $ | 1.0292 |   |
| 2008 Plan                                                 |   |      | 2,000,000  |   |          |   | —   |             |   | $ | — |   |   |   | — |   |   | $ | — |   |
| 2007 Plan frozen                                          |   |      | (10,500    | )      |          |   | —   |             |   | $ | — |   |   |   | — |   |   | $ | — |   |
| Granted                                                   |   |      | (1,807,000 | )      |          |   | 1,807,000 |             |   | $ | 1.6704 |   |   |   | — |   |   | $ | — |   |
| Exercised                                                 |   |      | —    |   |          |   | (27,536   | )                |   | $ | 0.1482 |   |   |   | — |   |   | $ | — |   |
| Vested                                                    |   |      | —    |   |          |   | —   |             |   | $ | — |   |   |   | (14,173 | ) |   | $ | 1.0071 |   |
| Forfeited                                                 |   |      | 161,500    |   |          |   | (310,458  | )                |   | $ | 2.0023 |   |   |   | — |   |   | $ | — |   |
| Cancelled                                                 |   |      | —    |   |          |   | (51,042   | )                |   | $ | 1.9751 |   |   |   | — |   |   | $ | — |   |
|                                                      |   |      |       |   |          |   |      |             |   |   |   |   |   |   |   |   |   |   |   |   |
|     Balance at December 31, 2008 |   |      | 734,500    |   |          |   | 3,686,700 |             |   | $ | 1.4505 |   |   |   | 22,383 |   |   | $ | 1.0432 |   |
| 2008 Plan Amendment                                       |   |      | 1,500,000  |   |          |   | —   |             |   | $ | — |   |   |   | — |   |   | $ | — |   |
| Granted                                                   |   |      | (1,257,000 | )      |          |   | 1,127,000 |             |   | $ | 1.6207 |   |   |   | 130,000 |   |   | $ | 2.0154 |   |
| Exercised                                                 |   |      | —    |   |          |   | (38,819   | )                |   | $ | 1.0298 |   |   |   | — |   |   | $ | — |   |
| Vested                                                    |   |      | —    |   |          |   | —   |             |   | $ | — |   |   |   | (144,175 | ) |   | $ | 1.9163 |   |
| Forfeited                                                 |   |      | 310,479    |   |          |   | (393,135  | )                |   | $ | 1.5072 |   |   |   | — |   |   | $ | — |   |
| Cancelled                                                 |   |      | 150,000    |   |          |   | (232,344  | )                |   | $ | 2.7135 |   |   |   | — |   |   | $ | — |   |
|                                                      |   |      |       |   |          |   |      |             |   |   |   |   |   |   |   |   |   |   |   |   |
|     Balance at December 31, 2009 |   |      | 1,437,979  |   |          |   | 4,149,402 |             |   | $ | 1.4246 |   |   |   | 8,208 |   |   | $ | 1.1055 |   |

----

|     | Options Outstanding         |                      | Options Exercisable |                        |
|----------|-----------------------------|---------------------------|---------------------|-----------------------------|
|     |                        |                      |                | Weighted                    |   |   |   |   | Weighted |   |   |   |
|     |                        |                      | Number              | Average                     | Weighted | Number | Average | Weighted |   |
| Range of | Outstanding                 | Remaining                 | Average             | Exercisable                 | Remaining | Average |   |
| Exercise | as of                       | Contractual               | Exercise            | as of                       | Contractual | Exercise |   |
| Prices   | December 31, 2009 | Life (in Years) | Price               | December 31, 2009 | Life (in Years) | Price |   |
|     |                        |                      |                |                        |   |   |   |   |   |   |   |   |   |   |
| $        | 0.0002                      | -                         | $0.0185             |   191,668              | 4.30 |   | $ | 0.0064 |   |   191,668 | 4.30 |   | $ | 0.0064 |   |
| $        | 0.1482                      | -                         | $0.4630             |   429,234              | 6.86 |   | $ | 0.3561 |   |   402,692 | 6.87 |   | $ | 0.3667 |   |
| $        | 0.6000                      | -                         | $1.0000             |   273,000              | 5.87 |   | $ | 0.9414 |   |   156,334 | 5.89 |   | $ | 0.8977 |   |
| $        | 1.1000                      | -                         | $1.6500             | 1,892,000                   | 6.75 |   | $ | 1.4060 |   |   913,935 | 7.05 |   | $ | 1.4738 |   |
| $        | 1.7800                      | -                         | $2.2500             | 1,363,500                   | 7.19 |   | $ | 2.0829 |   |   853,605 | 7.14 |   | $ | 2.1319 |   |
|     |                        |                      |                |                        |   |   |   |   |   |   |   |   |   |   |   |
|     |                        |                      |                | 4,149,402                   | 6.73 |   | $ | 1.4246 |   | 2,518,234 | 6.77 |   | $ | 1.3724 |   |

----

|   |                                      | December 31, 2009 |   |
|--------|-------------------------------------------|-------------------|--------|
|   |                                      |              |   |
|   | Risk-free interest rate                   | 1.16% - 2.16%     |   |
|   |                                      |              |   |
|   | Expected remaining term                   | 2.71 - 4.00 Years |   |
|   |                                      |              |   |
|   | Expected volatility                       | 43.26% - 49.78%   |   |
|   |                                      |              |   |
|   | Dividend yield                            | 0%                |   |
|   |                                      |              |   |
|   | Private Placement discount to stock price | 15%               |   |

----

| Securities into which    |   | Warrants    |   | Warrants subject |   | Exercise |   | Expiration |
|--------------------------|--------|-------------|--------|------------------|--------|----------|--------|------------|
| warrants are convertible |   | outstanding |   | to anti-dilution |   | Price    |   | Date       |
|                     |   |        |   |             |   |     |   |       |
| Common Stock             |   | 44,401      |   |   —   |   | $        | 1.41   |       | March 2012 |
| Common Stock             |   | 1,795,062   |   | 1,795,062        |   | $        | 1.95   |       | June and August 2014 |
| Common Stock             |   | 2,916,459   |   |   —   |   | $        | 2.25   |       | May and June 2012 |
| Common Stock             |   | 942,877     |   | 942,877          |   | $        | 2.50   |       | December 2014 |
| Common Stock             |   | 752,040     |   | 752,040          |   | $        | 2.53   |       | May  2013 |
| Common Stock             |   | 150,000     |   |   —   |   | $        | 3.00   |       | November  2015 |
| Common Stock             |   | 50,000      |   |   —   |   | $        | 3.25   |       | December 2014 |
|                     |   |        |   |             |   |     |   |       |   |
| Total                    |   | 6,650,839   |   | 3,489,979        |   |     |   |       |   |

|                       |   |              |    |   |              |   |    | Period From            |   |
|----------------------------|--------|-------------------|---------|--------|-------------------|--------|---------|-----------------------------|--------|
|                       |   |              |    |   |              |   |    | October 22, 2002  |   |
|                       |   | December 31, |    |   | December 31, |   |    | (Inception) to              |   |
|                       |   | 2009              |    |   | 2008              |   |    | December 31, 2009 |   |
|                       |   |              |    |   |              |   |    |                        |   |
| Current:                   |   |              |    |   |              |   |    |                        |   |
| Federal                    |   | $                 | — |   |              | $      | — |                        |   | $ | — |   |
| State                      |   |              | — |   |              |   | — |                        |   |   | — |   |
| Foreign                    |   |              | — |   |              |   | — |                        |   |   | — |   |
|                       |   |              |    |   |              |   |    |                        |   |   |   |   |
| Total Current              |   | $                 | — |   |              | $      | — |                        |   | $ | — |   |
|                       |   |              |    |   |              |   |    |                        |   |   |   |   |
| Deferred:                  |   |              |    |   |              |   |    |                        |   |   |   |   |
| Federal                    |   | $                 | — |   |              | $      | — |                        |   | $ | — |   |
| State                      |   |              | — |   |              |   | — |                        |   |   | — |   |
| Foreign                    |   |              | — |   |              |   | — |                        |   |   | — |   |
|                       |   |              |    |   |              |   |    |                        |   |   |   |   |
| Total Deferred             |   | $                 | — |   |              | $      | — |                        |   | $ | — |   |
|                       |   |              |    |   |              |   |    |                        |   |   |   |   |
| Provision for income taxes |   | $                 | — |   |              | $      | — |                        |   | $ | — |   |

----

|                                                 |              |   |              |   | Period From            |   |
|------------------------------------------------------|-------------------|--------|-------------------|--------|------------------------|--------|
|                                                 |              |   |              |   | October 22, 2002  |   |
|                                                 | December 31, |   | December 31, |   | (Inception) to         |   |
|                                                 | 2009              |   | 2008              |   | December 31, 2009 |   |
|                                                 |              |   |              |   |                   |   |
| Provision for income taxes at federal statutory rate |              | $      | (3,610,966        | )      |                   | $      | (2,746,980 | ) |   | $ | (10,368,895 | ) |
| Federal research and development tax credits         |              |   | (155,210          | )      |                   |   | (150,000 | ) |   |   | (594,389 | ) |
| Expenses not deductible                              |              |   | 392,386           |   |                   |   | 137,379 |   |   |   | 990,272 |   |
| Foreign loss taxed at lower rates                    |              |   | 44,792            |   |                   |   | 64,774 |   |   |   | 109,566 |   |
| Change in federal valuation allowance                |              |   | 3,328,998         |   |                   |   | 2,694,827 |   |   |   | 9,863,446 |   |
|                                                 |              |   |              |   |                   |   |   |   |   |   |   |   |
|  Provision for income taxes                     |              | $      | —           |   |                   | $      | — |   |   | $ | — |   |

|                                                        |   | December 31, |        |   | December 31, |   |
|-------------------------------------------------------------|--------|-------------------|-------------|--------|-------------------|--------|
|                                                        |   | 2009              |        |   | 2008              |   |
|                                                        |   |              |        |   |              |   |
| Deferred tax assets:                                        |   |              |        |   |              |   |
| Net operating loss carryforwards                            |   | $                 | 9,703,709   |   |              | $      | 6,613,525 |   |
| Capitalized start-up cost and research and development cost |   |              | 851,082     |   |              |   | 915,399 |   |
| Research and development tax credit                         |   |              | 973,788     |   |              |   | 700,546 |   |
| Depreciation on property and equipment                      |   |              | 38,410      |   |              |   | 12,603 |   |
| Reserves and accruals                                       |   |              | 201,797     |   |              |   | 81,949 |   |
|                                                        |   |              |        |   |              |   |   |   |
| Total deferred tax asset                                    |   |              | 11,768,786  |   |              |   | 8,324,022 |   |
|                                                        |   |              |        |   |              |   |   |   |
| Valuation allowance                                         |   |              | (11,768,786 | )      |              |   | (8,324,022 | ) |
|                                                        |   |              |        |   |              |   |   |   |
| Net deferred tax assets                                     |   | $                 | —     |   |              | $      | — |   |

|                                                        | December 31, |   | December 31, |   |   | Period FromOctober 22, 2002(Inception) to |       |
|-------------------------------------------------------------|-------------------|--------|-------------------|--------|--------|-----------------------------------------------------|------------|
|                                                        | 2009              |   | 2008              |   |   | December 31, 2009                              |       |
|                                                        |              |   |              |   |   |                                                |       |
| Deferred tax assets:                                        |              |   |              |   |   |                                                |       |
| Net operating loss carryforwards                            |              | $      | 3,090,184         |   |   | $                                                   | 3,388,042  |   |   | $ | 9,703,709 |   |
| Capitalized start-up cost and research and development cost |              |   | (64,317           | )      |   |                                                | (130,771   | ) |   |   | 851,082 |   |
| Research and development tax credit                         |              |   | 273,242           |   |   |                                                | 117,564    |   |   |   | 973,788 |   |
| Depreciation on property and equipment                      |              |   | 25,807            |   |   |                                                | (9,167     | ) |   |   | 38,410 |   |
| Reserves and accruals                                       |              |   | 119,848           |   |   |                                                | (97,972    | ) |   |   | 201,797 |   |
| Valuation allowance                                         |              |   | (3,444,764        | )      |   |                                                | (3,267,696 | ) |   |   | (11,768,786 | ) |
|                                                        |              |   |              |   |   |                                                |       |   |   |   |   |   |
| Net deferred income taxes                                   |              | $      | —           |   |   | $                                                   | —    |   |   | $ | — |   |

----

|         |                         |   | Period FromOctober 22, 2002 |   |
|--------------|------------------------------|--------|---------------------------------------|--------|
|         | Year Ended December 31, |   | (Inception) to                   |   |
|         | 2009                         |   | 2008                                  |   | December 31, 2009 |   |
|         |                         |   |                                  |   |   |   |
| Interest     |                         | $      | 9,204                                 |   |   | $ | 14,851 |   |   | $ | 42,541 |   |
|         |                         |   |                                  |   |   |   |   |   |   |   |   |   |
| Income taxes |                         | $      | —                               |   |   | $ | — |   |   | $ | — |   |

----

|                                                  |   |                                   |    |   | Period From           |   |
|-------------------------------------------------------|--------|----------------------------------------|---------|--------|----------------------------|--------|
|                                                  |   |                                   |    |   | October 22, 2002 |   |
|                                                  |   | Year Ended December 31, |    |   | (Inception) to             |   |
|                                                  |   | 2009                                   |    |   | 2008                       |   |   | December 31, 2009 |   |
|                                                  |   |                                   |    |   |                       |   |   |   |   |
| Accretion on Series B Preferred Stock                 |   | $                                      | — |   |                       | $      | — |   |   | $ | 155,998 |   |
|                                                  |   |                                   |    |   |                       |   |   |   |   |   |   |   |
| Accretion on Redeemable Convertible Preference Shares |   | $                                      | 178,162 |   |                       | $      | 37,916 |   |   | $ | 216,078 |   |
|                                                  |   |                                   |    |   |                       |   |   |   |   |   |   |   |
| Conversion of due to a stockholder to notes payable   |   | $                                      | — |   |                       | $      | — |   |   | $ | 61,588 |   |
|                                                  |   |                                   |    |   |                       |   |   |   |   |   |   |   |
| Issuance of warrants with notes payable               |   | $                                      | — |   |                       | $      | — |   |   | $ | 171,053 |   |
|                                                  |   |                                   |    |   |                       |   |   |   |   |   |   |   |
| Conversion of debt to Common Stock                    |   | $                                      | — |   |                       | $      | — |   |   | $ | 240,000 |   |
|                                                  |   |                                   |    |   |                       |   |   |   |   |   |   |   |
| Conversion of debt to Series A Preferred Stock        |   | $                                      | — |   |                       | $      | — |   |   | $ | 2,977,579 |   |
|                                                  |   |                                   |    |   |                       |   |   |   |   |   |   |   |
| Deposit in equipment in 2007 lapsed in 2008           |   | $                                      | — |   |                       | $      | 51,446 |   |   | $ | 51,446 |   |
|                                                  |   |                                   |    |   |                       |   |   |   |   |   |   |   |
| Property and equipment acquired with capital leases   |   | $                                      | — |   |                       | $      | 131,550 |   |   | $ | 256,326 |   |
|                                                  |   |                                   |    |   |                       |   |   |   |   |   |   |   |
| Issuance of warrants to agents with private placement |   | $                                      | 286,315 |   |                       | $      | — |   |   | $ | 352,634 |   |
|                                                  |   |                                   |    |   |                       |   |   |   |   |   |   |   |
| Cumulative effect of reclassification of warrants     |   | $                                      | 99,444  |   |                       | $      | — |   |   | $ | 99,444 |   |

----

|   | Level 1 - Quoted prices in active markets that are unadjusted and accessible at the measurement date for identical, unrestricted assets or liabilities; |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Level 2 - Quoted prices for identical assets and liabilities in markets that are not active, quoted prices for similar assets and liabilities in active markets or financial instruments for which significant inputs are observable, either directly or indirectly; |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------|

|                                                   |   | Level 1 |      |   | Level 2 |   |    | Level 3 |   |   | Total     |   |
|--------------------------------------------------------|--------|--------------|-----------|--------|--------------|--------|---------|--------------|--------|--------|-----------|--------|
|                                                   |   |         |      |   |         |   |    |         |   |   |      |   |
|     Financial Assets:              |   |         |      |   |         |   |    |         |   |   |      |   |
|     Cash and cash equivalents      |   | $            | 5,953,639 |   |         | $      | — |         |   | $      | —   |   |   | $ | 5,953,639 |   |
|                                                   |   |         |      |   |         |   |    |         |   |   |      |   |   |   |   |   |
|     Financial Liabilities:         |   |         |      |   |         |   |    |         |   |   |      |   |   |   |   |   |
|     Warrant derivative liabilities |   | $            | —   |   |         | $      | — |         |   | $      | 2,778,191 |   |   | $ | 2,778,191 |   |

|     Balance at January 1, 2009                                 |   |   |    |   | $      | — |      |
|-----------------------------------------------------------------------------------------|--------|--------|---------|--------|--------|---------|-----------|
|     Additions - fair value of warrants issued in June 2009     |   | $      | 669,525 |   |   |    |      |   |
|     Additions - fair value of warrants issued in August 2009   |   |   | 484,869 |   |   |    |      |   |
|     Additions - fair value of warrants issued in December 2009 |   |   | 960,231 |   |   |    |      |   |
|     Total additions                                                 |   |   |    |   |   |    | 2,114,625 |   |
|       Change in unrealized (gains) losses, net (1)        |   |   |    |   |   |    | 564,122   |   |
|       Transfers (2)                                       |   |   |    |   |   |    | 99,444    |   |
|     Balance at December 31, 2009                               |   |   |    |   |   | $       | 2,778,191 |   |

| (1)   | Reported in the Statement of Operations. |
|-----------------|------------------------------------------|

| (2)   | Represents the $99,444 cumulative effect change in accounting principle as a result of the Company adopting FASB ASC Topic No. 815 - 40 (formerly EITF 07-5) effective January 1, 2009. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                                                                                          |   |   | 2009    |   |   | 2008   |    |
|---------------------------------------------------------------------------------------------------------------|--------|--------|---------|--------|--------|--------|---------|
|                                                                                                          |   |   |    |   |   |   |    |
|     North America                                                                         |   | $      | 346,185 |   |   | $      | 318,377 |   |
|     Asia                                                                                  |   |   | 1,035   |   |   |   | 60,773  |   |
|     Europe                                                                                |   |   | 32,153  |   |   |   | 210,330 |   |
|     Other                                                                                 |   |   | — |   |   |   | 32,386  |   |
|                                                                                                          |   |   |    |   |   |   |    |   |
|                 Total revenue |   | $      | 379,373 |   |   | $      | 621,866 |   |

|                                                  |   | 2009    |    |   | 2008   |    |
|-------------------------------------------------------|--------|---------|---------|--------|--------|---------|
|                                                  |   |    |    |   |   |    |
|     United States                 |   | $       | 287,770 |   |   | $       | 613,256 |   |
|     Malaysia                      |   |    | 154,226 |   |   |    | 182,083 |   |
|                                                  |   |    |    |   |   |    |   |   |
|      Total long-lived assets | $      | 441,996 |    |   | $      | 795,339 |   |

----

|                                       |   | Year Ended December 31, 2009 |       |
|--------------------------------------------|--------|-----------------------------------|------------|
|                                       |   | First                             |       |   | Second |   |   | Third |   |   | Fourth |   |
| As restated                                |   |                              |       |   |   |   |   |   |   |   |   |   |
| Revenue                                    |   | $                                 | 41,838     |   |   | $ | 68,918 |   |   | $ | 78,860 |   |   | $ | 189,757 |   |
| Gross margin                               |   | $                                 | 26,006     |   |   | $ | (55,014 | ) |   | $ | 11,963 |   |   | $ | 133,377 |   |
| Net loss                                   |   | $                                 | (1,764,057 | ) |   | $ | (2,836,659 | ) |   | $ | (3,012,482 | ) |   | $ | (3,007,290 | ) |
| Net loss applicable to common stockholders |   | $                                 | (1,799,057 | ) |   | $ | (2,873,075 | ) |   | $ | (3,056,158 | ) |   | $ | (3,070,360 | ) |
| Net loss per share - basic and diluted     |   | $                                 | (0.07      | ) |   | $ | (0.11 | ) |   | $ | (0.11 | ) |   | $ | (0.10 | ) |

|                                       |   | Year Ended December 31, 2009 |       |
|--------------------------------------------|--------|-----------------------------------|------------|
|                                       |   | First                             |       |   | Second |   |   | Third |   |   | Fourth |   |
| As previously reported                     |   |                              |       |   |   |   |   |   |   |   |   |   |
| Revenue                                    |   | $                                 | 41,838     |   |   | $ | 68,918 |   |   | $ | 78,860 |   |   | $ | 189,757 |   |
| Gross margin                               |   | $                                 | 26,006     |   |   | $ | (55,014 | ) |   | $ | 11,963 |   |   | $ | 133,377 |   |
| Net loss                                   |   | $                                 | (1,777,800 | ) |   | $ | (2,870,984 | ) |   | $ | (2,464,031 | ) |   | $ | (2,943,551 | ) |
| Net loss applicable to common stockholders |   | $                                 | (1,812,800 | ) |   | $ | (2,907,400 | ) |   | $ | (2,507,707 | ) |   | $ | (3,006,621 | ) |
| Net loss per share - basic and diluted     |   | $                                 | (0.07      | ) |   | $ | (0.11 | ) |   | $ | (0.09 | ) |   | $ | (0.10 | ) |

|                                        |   | Year Ended December 31, 2008 |       |
|---------------------------------------------|--------|-----------------------------------|------------|
|                                        |   | First                             |       |   | Second |   |   | Third |   |   | Fourth |   |
| No changes from previously reported amounts |   |                              |       |   |   |   |   |   |   |   |   |   |
| Revenue                                     |   | $                                 | 181,640    |   |   | $ | 176,851 |   |   | $ | 197,951 |   |   | $ | 65,424 |   |
| Gross margin                                |   | $                                 | 106,623    |   |   | $ | 119,803 |   |   | $ | 123,995 |   |   | $ | 30,412 |   |
| Net loss                                    |   | $                                 | (1,892,291 | ) |   | $ | (2,143,217 | ) |   | $ | (2,070,317 | ) |   | $ | (1,935,612 | ) |
| Net loss applicable to common stockholders  |   | $                                 | (1,892,291 | ) |   | $ | (2,143,217 | ) |   | $ | (2,084,900 | ) |   | $ | (1,958,945 | ) |
| Net loss per share - basic and diluted      |   | $                                 | (0.08      | ) |   | $ | (0.09 | ) |   | $ | (0.08 | ) |   | $ | (0.08 | ) |

----

|                                            | December 31, 2009 |   |
|-------------------------------------------------|------------------------|--------|
|                                            | As Previously     |   |   |   |   |   |   |
|                                            | Reported               |   | Adjustment |   |   | As Restated |   |
| Consolidated Balance Sheet Data: |                   |   |   |   |   |   |   |   |   |   |
| Warrant derivative liability                    |                   | $      | — |   |   | $ | 2,778,191 |   | (1) |   | $ | 2,778,191 |   |
| Additional paid-in capital                      |                   |   | 31,600,274 |   |   |   | (2,582,696 | ) | (2) |   |   | 29,017,578 |   |
| Accumulated deficit                             |                   |   | (30,266,788 | ) |   |   | (195,495 | ) | (3) |   |   | (30,462,283 | ) |
| Total stockholders’ equity (deficit)      |                   |   | 1,430,255 |   |   |   | (2,778,191 | ) |   |   |   | (1,347,936 | ) |

|                                                                 |   | December 31, 2009 |        |
|----------------------------------------------------------------------|--------|------------------------|-------------|
|                                                                 |   | As Previously     |        |   |   |   |   |   |   |   |
|                                                                 |   | Reported               |        |   | Adjustment |   |   |   | As Restated |   |
| Consolidated Statements of Operations Data:                |   |                   |        |   |   |   |   |   |   |   |
| Revenue                                                              |   | $                      | 379,373     |   |   | $ | — |   |   |   | $ | 379,373 |   |
| Gross margin                                                         |   |                   | 116,332     |   |   |   | — |   |   |   |   | 116,332 |   |
| Operating loss                                                       |   |                   | (10,010,078 | ) |   |   | — |   |   |   |   | (10,010,078 | ) |
| Unrealized loss on fair value of warrants, net                       |   |                   | —     |   |   |   | (564,122 | ) | (4) |   |   | (564,122 | ) |
| Total other income and (expenses)                                    |   |                   | (46,288     | ) |   |   | (564,122 | ) |   |   |   | (610,410 | ) |
| Net loss                                                             |   |                   | (10,056,366 | ) |   |   | (564,122 | ) |   |   |   | (10,620,488 | ) |
| Net loss applicable to common stockholders                           |   |                   | (10,234,528 | ) |   |   | (564,122 | ) |   |   |   | (10,798,650 | ) |
| Net loss per share - basic and diluted                               |   |                   | (0.37       | ) |   |   | (0.02 | ) |   |   |   | (0.39 | ) |
|                                                                 |   |                   |        |   |   |   |   |   |   |   |   |   |   |
| Consolidated Statements of Cash Flows Data: |   |                   |        |   |   |   |   |   |   |   |   |   |   |
| Net loss                                                             |   |                   | (10,056,366 | ) |   |   | (564,122 | ) |   |   |   | (10,620,488 | ) |
| Unrealized loss on fair value of warrants, net                       |   |                   | —     |   |   |   | 564,122 |   |   |   |   | 564,122 |   |
| Net cash used in operating activities                                |   |                   | (7,832,332  | ) |   |   | — |   |   |   |   | (7,832,332 | ) |

| (1)   | Represents the warrant derivative liability balance as at December 31, 2009 related to 3,489,979 warrants with anti-dilution provisions (see Note 8). |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | Represents the issuance date fair value of warrants with anti-dilution provisions issued in May 2008, and June, August and December 2009 (see Note 8). |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3)   | Represents the cumulative net unrealized loss arising from the revaluation of outstanding warrants with anti-dilution provisions, including an unrealized gain that would have been recorded in the year ended December 31, 2008 had ASC 815-40 been in effect for that year. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4)   | Represents the cumulative net unrealized loss arising from the revaluation of outstanding warrants with anti-dilution provisions that arose in the year ended December 31, 2009. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 1. | We had not designed or otherwise maintained adequate controls to ensure that we adopted new accounting policies with respect to non-routine matters, such as the accounting of warrants with anti-dilution protection.  In particular, subsequent to the filing of the Original Report on March 22, 2010, we determined that FASB ASC 815-40-15-5 (“ASC 815-40”, formerly EITF 07-5), “Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock”, had not been properly adopted on January 1, 2009 with regard to certain warrants we previously issued, and we thereafter determined that certain prior period financial statements required restatement. As a result, as disclosed in the Explanatory Note on page 2 of this Form 10-K/A and in Note 16 to our consolidated financial statements included in this Form 10-K/A, we restated our consolidated financial statements as of and for the fiscal year ended December 31, 2009 and each of the quarterly periods in the fiscal year ended December 31, 2009; |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | We have not adequately divided, or compensated for, incompatible functions among personnel to reduce the risk that a potential material misstatement of the financial statements would occur without being prevented or detected; and |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | We have insufficient documentation of our information technology general control environment. |
|--------|----|-----------------------------------------------------------------------------------------------|

----

|   | 1. | We have designed new controls to help ensure that we adopt new accounting policies with respect to non-routine matters on a timely manner. We have provided further technical training to our accounting personnel relating to the timely adoption of new accounting pronouncements in the future and intend to provide additional such training in the future. With respect to the adoption of ASC 815-40 in particular, we have provided additional technical training to our accounting personnel on the appropriate accounting requirements for convertible securities and the valuation models and processes required with respect to the accounting of convertible securities, and we have engaged outside experts to assist the Company with the periodic valuations of any such convertible securities. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | We have introduced employee access restrictions within our accounting system, in accordance with the formally adopted Financial Delegation Policy, which is kept up to date. Further, we have formalized procedures for independent review and approval. Nevertheless, as a small company, we do not have the resources to fund sufficient staff to ensure a complete segregation of responsibilities within the accounting function, and we remain reliant on management oversight. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | We intend to hire a full-time IT employee, who will design and document procedures addressing our information technology general controls and management information systems. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------|

| ·   | were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit      |   |                                                                                                                                         |   | Filed    |   | Incorporated by Reference |
|--------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------|--------|----------|--------|-------------------------------------|
| Number       |   | Exhibit Description                                                                                                                          |   | Herewith |   | Form                                |   | Period Ending |   | Exhibit |   | Filing Date |
|         |   |                                                                                                                                         |   |     |   |                                |   |   |   |   |   |   |
| 2.1          |   | Agreement and Plan of Merger and Reorganization, dated as of May 31, 2007, by and among WBSI, WaferGen Acquisition Corp., and WaferGen, Inc. |   |     |   | 8-K                                 |   |   |   | 2.1 |   | 6/5/2007 |
|         |   |                                                                                                                                         |   |     |   |                                |   |   |   |   |   |   |
| 2.2          |   | Certificate of Merger of WaferGen Acquisition Corp. with and into WaferGen, Inc., dated May 31, 2007                                         |   |     |   | 8-K                                 |   |   |   | 2.2 |   | 1/16/2008 |
|         |   |                                                                                                                                         |   |     |   |                                |   |   |   |   |   |   |
| 3.1          |   | Certificate of Incorporation of WBSI                                                                                                         |   |     |   | SB-2                                |   |   |   | 3.1 |   | 8/9/2006 |
|         |   |                                                                                                                                         |   |     |   |                                |   |   |   |   |   |   |
| 3.2          |   | Certificate of Amendment to the Certificate of Incorporation of WBSI, dated January 31, 2007                                                 |   |     |   | 8-K                                 |   |   |   | 3.1 |   | 2/1/2007 |
|         |   |                                                                                                                                         |   |     |   |                                |   |   |   |   |   |   |
| 3.3          |   | Bylaws of WBSI                                                                                                                               |   |     |   | SB-2                                |   |   |   | 3.2 |   | 8/9/2006 |
|         |   |                                                                                                                                         |   |     |   |                                |   |   |   |   |   |   |
| 4.1          |   | Lockup Agreement dated January 14, 2008, among WBSI, Rodman & Renshaw LLC and R&R Biotech Partners LLC                               |   |     |   | SB-2/A                              |   |   |   | 4.1 |   | 1/16/2008 |
|         |   |                                                                                                                                         |   |     |   |                                |   |   |   |   |   |   |
| 10.1 † |   | Form of Warrants, made as of May 5, 2007, to purchase up to an aggregate of 115,424 shares of WBSI’s Common Stock                      |   |     |   | 10-K                                |   | 12/31/2009 |   | 10.1 |   | 3/22/2010 |
|         |   |                                                                                                                                         |   |     |   |                                |   |   |   |   |   |   |
| 10.2         |   | Form of Common Stock Purchase Warrant issued to investors in a private placement, the initial closing of which was held on May 31, 2007      |   |     |   | 8-K                                 |   |   |   | 10.21 |   | 6/5/2007 |
|         |   |                                                                                                                                         |   |     |   |                                |   |   |   |   |   |   |
| 10.3         |   | Form of Warrant issued to Placement Agent in connection with a private placement, the initial closing of which was held on May 31, 2007      |   |     |   | 8-K                                 |   |   |   | 10.22 |   | 6/5/2007 |
|         |   |                                                                                                                                         |   |     |   |                                |   |   |   |   |   |   |

----

| Exhibit       |   |                                                                                                                                                                                                                                                                                                     |   | Filed    |   | Incorporated by Reference |
|---------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------|--------|-------------------------------------|
| Number        |   | Exhibit Description                                                                                                                                                                                                                                                                                      |   | Herewith |   | Form                                |   | Period Ending |   | Exhibit |   | Filing Date |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.4 †  |   | Employment Agreement dated May 31, 2007, between WBSI and Alnoor Shivji                                                                                                                                                                                                                                  |   |     |   | 8-K                                 |   |   |   | 10.26 |   | 6/5/2007 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.5          |   | Securities Purchase Agreement, dated May 19, 2008, by and among WaferGen Bio-systems, Inc. and the purchasers identified on the signature pages thereto                                                                                                                                                  |   |     |   | 8-K                                 |   |   |   | 10.1 |   | 5/21/2008 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.6          |   | Form of Common Stock Purchase Warrant issued to investors identified in the Securities Purchase Agreement dated May 19, 2008                                                                                                                                                                             |   |     |   | 8-K                                 |   |   |   | 10.2 |   | 5/21/2008 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.7 †  |   | WaferGen Bio-Systems, Inc. 2008 Stock Incentive Plan                                                                                                                                                                                                                                                     |   |     |   | 8-K                                 |   |   |   | 10.1 |   | 7/3/2008 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.8 †  |   | Form of Non-Qualified Stock Option award under 2008 Stock Incentive Plan                                                                                                                                                                                                                                 |   |     |   | 10-K                                |   | 12/31/2008 |   | 10.35 |   | 3/27/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.9          |   | Share Subscription Agreement and Shareholders’ Agreement dated May 8, 2008, by and among WaferGen Bio-systems, Inc., Malaysian Technology Development Corporation Sdn. Bhd. and WaferGen Biosystems (M) Sdn. Bhd.                                                                                  |   |     |   | 10-Q                                |   | 9/30/2008 |   | 10.1 |   | 11/14/2008 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.10         |   | Put Agreement dated May 28, 2008, by and among WaferGen Bio-systems, Inc. and Holders of the Series A Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                      |   |     |   | 10-Q                                |   | 9/30/2008 |   | 10.2 |   | 11/14/2008 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.11         |   | Put Option Agreement dated May 28, 2008, by and among Alnoor Shivji and Malaysian Technology Development Corporation Sdn. Bhd.                                                                                                                                                                           |   |     |   | 10-Q                                |   | 9/30/2008 |   | 10.3 |   | 11/14/2008 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.12 † |   | Letter Agreement dated January 16, 2009, by and between WBSI and Alnoor Shivji                                                                                                                                                                                                                           |   |     |   | 10-K                                |   | 12/31/2008 |   | 10.39 |   | 3/27/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.13         |   | Form of WBSI Distribution Agreement                                                                                                                                                                                                                                                                      |   |     |   | 10-K                                |   | 12/31/2008 |   | 10.42 |   | 3/27/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.14         |   | Share Subscription Agreement dated April 3, 2009, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd., Primar Mahawangsa Sdn. Bhd. and Expedient Equity Ventures Sdn. Bhd.                                                                                                        |   |     |   | 8-K                                 |   |   |   | 10.1 |   | 4/14/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.15         |   | Put Agreement dated April 3, 2009, by and among WaferGen Bio-systems, Inc. and Holders of Series B Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                         |   |     |   | 8-K                                 |   |   |   | 10.2 |   | 4/14/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.16         |   | Form of Put Option Agreement dated April 3, 2009, by and among Alnoor Shivji and Holders of Series B Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                       |   |     |   | 8-K                                 |   |   |   | 10.3 |   | 4/14/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.17         |   | Deed of Adherence to the Share Subscription and Shareholders’ Agreement dated May 8, 2008, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd., Primar Mahawangsa Sdn. Bhd., Expedient Equity Ventures Sdn. Bhd. and Malaysian Technology Development Corporation Sdn. Bhd. |   |     |   | 10-Q                                |   | 3/31/2009 |   | 10.4 |   | 5/12/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.18         |   | Form of Subscription Agreement between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s 2009 private placement offering of units of securities                                                                                                         |   |     |   | 10-Q                                |   | 6/30/2009 |   | 10.5 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.19         |   | Form of Warrants to purchase shares of Common Stock of the Company, issued June 16, 2009, to investors in the Company’s 2009 private placement offering of units of securities                                                                                                                     |   |     |   | 10-Q                                |   | 6/30/2009 |   | 10.6 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.20         |   | Registration Rights Agreement, dated June 16, 2009, between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s 2009 private placement offering of units of securities                                                                                    |   |     |   | 10-Q                                |   | 6/30/2009 |   | 10.7 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.21         |   | Form of Warrant to purchase shares of Common Stock of the Company, issued to Spencer Trask Ventures, Inc. and certain related parties in connection with the Company’s 2009 private placement offering of units of securities                                                                      |   |     |   | 10-Q                                |   | 6/30/2009 |   | 10.8 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.22 † |   | Employment Separation Agreement, dated June 17, 2009, by and among Amjad Huda and WaferGen Bio-systems, Inc.                                                                                                                                                                                             |   |     |   | 10-K                                |   | 12/31/2009 |   | 10.22 |   | 3/22/2010 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.23 † |   | Employment Separation Agreement, dated June 17, 2009, by and among Victor Joseph and WaferGen Bio-systems, Inc.                                                                                                                                                                                          |   |     |   | 10-K                                |   | 12/31/2009 |   | 10.23 |   | 3/22/2010 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |
| 10.24         |   | Share Subscription Agreement dated July 1, 2009, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd. and Kumpalan Modal Perdana Sdn. Bhd.                                                                                                                                         |   |     |   | 10-Q                                |   | 9/30/2009 |   | 10.1 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                     |   |     |   |                                |   |   |   |   |   |   |

----

| Exhibit       |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   | Filed    |   | Incorporated by Reference |
|---------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------|--------|-------------------------------------|
| Number        |   | Exhibit Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |   | Herewith |   | Form                                |   | Period Ending |   | Exhibit |   | Filing Date |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 10.25         |   | Put Agreement dated July 1, 2009, by and among WaferGen Bio-systems, Inc. and Holders of Series B Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                                                                                                                                                                                                        |   |     |   | 10-Q                                |   | 9/30/2009 |   | 10.2 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 10.26         |   | Put Option Agreement dated July 1, 2009, by and among Alnoor Shivji and Kumpalan Modal Perdana Sdn. Bhd.                                                                                                                                                                                                                                                                                                                                                                               |   |     |   | 10-Q                                |   | 9/30/2009 |   | 10.3 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 10.27         |   | Deed of Adherence dated July 1, 2009, to the Share Subscription and Shareholders’ Agreement dated May 8, 2008, and the Share Subscription Agreement dated April 3, 2009, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd., Primar Mahawangsa Sdn. Bhd., Expedient Equity Ventures Sdn. Bhd., Malaysian Technology Development Corporation Sdn. Bhd. and Kumpalan Modal Perdana Sdn. Bhd.                                                               |   |     |   | 10-Q                                |   | 9/30/2009 |   | 10.4 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 10.28 † |   | Employment Agreement, effective October 29, 2009, by and between the Company and Mona Chadha                                                                                                                                                                                                                                                                                                                                                                                           |   |     |   | 10-Q                                |   | 9/30/2009 |   | 10.5 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 10.29         |   | Lease Agreement by and between WaferGen, Inc. and LBA Realty Fund III-Company VII, LLC dated October 22, 2009                                                                                                                                                                                                                                                                                                                                                                          |   |     |   | 10-Q                                |   | 9/30/2009 |   | 10.6 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 10.30 † |   | WaferGen Bio-Systems, Inc. 2008 Stock Incentive Plan, as amended                                                                                                                                                                                                                                                                                                                                                                                                                       |   |     |   | 8-K                                 |   |   |   | 10.1 |   | 12/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 10.31         |   | Form of Subscription Agreement between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s December 2009 and January 2010 private placement offering of units of securities                                                                                                                                                                                                                                                             |   |     |   | S-1                                 |   |   |   | 10.58 |   | 3/2/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 10.32         |   | Form of Warrants to purchase shares of Common Stock of the Company, issued December 23, 2009, to investors in the Company’s December 2009 and January 2010 private placement offering of units of securities                                                                                                                                                                                                                                                                     |   |     |   | S-1                                 |   |   |   | 10.59 |   | 3/2/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 10.33         |   | Registration Rights Agreement, dated December 23, 2009, between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s December 2009 and January 2010 private placement offering of units of securities                                                                                                                                                                                                                                    |   |     |   | S-1                                 |   |   |   | 10.60 |   | 3/2/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 21.1          |   | Subsidiaries of the Registrant                                                                                                                                                                                                                                                                                                                                                                                                                                                         |   |     |   | 10-K                                |   | 12/31/2008 |   | 21.1 |   | 3/27/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 23.1          |   | Letter of Consent from Independent Registered Public Accounting Firm, Rowbotham & Company LLP                                                                                                                                                                                                                                                                                                                                                                                      |   | X        |   |                                |   |   |   |   |   |   |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 31.1          |   | Rule 13a-14(a)/15d-14(a) Certification of principal executive officer                                                                                                                                                                                                                                                                                                                                                                                                                  |   | X        |   |                                |   |   |   |   |   |   |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 31.2          |   | Rule 13a-14(a)/15d-14(a) Certification of principal financial officer                                                                                                                                                                                                                                                                                                                                                                                                                  |   | X        |   |                                |   |   |   |   |   |   |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 32.1          |   | Section 1350 Certification of principal executive officer  (This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.) |   | X        |   |                                |   |   |   |   |   |   |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |     |   |                                |   |   |   |   |   |   |
| 32.2          |   | Section 1350 Certification of principal financial officer  (This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.) |   | X        |   |                                |   |   |   |   |   |   |

| † |   | Indicates a management contract or compensatory plan or arrangement. |
|---------|--------|----------------------------------------------------------------------|

----

|                    |   | WAFERGEN BIO-SYSTEMS, INC.       |   |
|-------------------------|--------|-------------------------------------------------|--------|
|                    | By:    |   /s/  Alnoor Shivji        |   |
| Date: May 12, 2010 |   | Alnoor Shivji                                   |   |
|                    |   | Chairman, President and Chief Executive Officer |   |

| SIGNATURE                                      |   |  TITLE                                                                   |   |  DATE        |
|------------------------------------------------|--------|-------------------------------------------------------------------------------|--------|-------------------|
|    /s/  Alnoor Shivji |   |                                                                          |   |              |
| Alnoor Shivji                   |   | Chairman, President and Chief Executive Officer (principal executive officer) |   | May 12, 2010 |
| /s/  Hector Brush                    |   |                                                                          |   |              |
| Hector Brush                    |   | Treasurer (principal financial officer)                                       |   | May 12, 2010 |
| /s/  Dr. R. Dean Hautamaki           |   |                                                                          |   |              |
| Dr. R. Dean Hautamaki           |   | Director                                                                      |   | May 12, 2010 |
| /s/  Joel Kanter                     |   |                                                                          |   |              |
| Joel Kanter                     |   | Director                                                                      |   | May 12, 2010 |
| /s/  Makoto Kaneshiro                |   |                                                                          |   |              |
| Makoto Kaneshiro                     |   | Director                                                                      |   | May 12, 2010 |
| /s/  Nadine Smith                    |   |                                                                          |   |              |
| Nadine Smith                         |   | Director                                                                      |   | May 12, 2010 |
|                                           |   |                                                                          |   |              |
| Dr. Robert Hariri                              |   | Director                                                                      |   |              |
|                                           |   |                                                                          |   |              |
|                                           |   |                                                                          |   |              |
| /s/  Robert Coradini                 |   |                                                                          |   |              |
| Robert Coradini                                |   | Director                                                                      |   | May 12, 2010 |

----

| Exhibit |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number  |   | Exhibit Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|    |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 23.1    |   | Letter of Consent from Independent Registered Public Accounting Firm, Rowbotham & Company LLP                                                                                                                                                                                                                                                                                                                                                                                      |
|    |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 31.1    |   | Rule 13a-14(a)/15d-14(a) Certification of principal executive officer                                                                                                                                                                                                                                                                                                                                                                                                                  |
|    |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 31.2    |   | Rule 13a-14(a)/15d-14(a) Certification of principal financial officer                                                                                                                                                                                                                                                                                                                                                                                                                  |
|    |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 32.1    |   | Section 1350 Certification of principal executive officer  (This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.) |
|    |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 32.2    |   | Section 1350 Certification of principal financial officer  (This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.) |

----

----

----

----

| 1. | I have reviewed this annual report on Form 10-K/A of WaferGen Bio-systems, Inc.; |
|----|---------------------------------------------------------------------------------------|

| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1. | I have reviewed this annual report on Form 10-K/A of WaferGen Bio-systems, Inc.; |
|----|---------------------------------------------------------------------------------------|

| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1. | The Annual Report of WaferGen Bio-systems, Inc. (the “Company”) on Form 10-K/A for the year ended December 31, 2009 (the “Report”) as filed with the Securities and Exchange Commission as of the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1. | The Annual Report of WaferGen Bio-systems, Inc. (the “Company”) on Form 10-K/A for the year ended December 31, 2009 (the “Report”) as filed with the Securities and Exchange Commission as of the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------|

----